Syndax Pharmaceuticals (SNDX)

Its lead oncology programme is revumenib, a selective inhibitor of the menin-MLL interaction. Syndax is developing the therapy for genetically defined acute leukemias, including KMT2A-rearranged and NPM1-mutant acute myeloid leukemia and acute lymphoblastic leukemia. These subtypes are associated with distinct molecular drivers, and Syndax’s approach is intended to interfere with the mechanisms that sustain leukemia cell growth.

The company is also developing axatilimab, an antibody that targets colony stimulating factor-1 receptor, or CSF-1R. This programme is directed at chronic graft-versus-host disease, a serious complication that can occur after allogeneic stem cell transplantation, and has also been studied in fibrotic and inflammatory conditions such as idiopathic pulmonary fibrosis. By targeting CSF-1R, axatilimab is designed to affect macrophage-driven disease processes that contribute to tissue damage and scarring.

Syndax’s earlier pipeline includes entinostat, an oral small-molecule HDAC inhibitor with potential effects on cancer cells and immune regulation. As a development-stage drug company, Syndax’s value depends heavily on clinical trial outcomes, regulatory progress, partnerships, and the commercial potential of its therapies if approved. The company operates primarily in the United States and is part of the broader biotechnology sector, where scientific differentiation and execution in clinical development are central to long-term performance.